Cholecystokinin B receptor agonists alleviates anterograde amnesia in cholecystokinin-deficient and aged Alzheimer's disease mice.


Journal

Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643

Informations de publication

Date de publication:
15 May 2024
Historique:
received: 06 09 2023
accepted: 01 05 2024
medline: 16 5 2024
pubmed: 16 5 2024
entrez: 15 5 2024
Statut: epublish

Résumé

As one major symptom of Alzheimer's disease (AD), anterograde amnesia describes patients with an inability in new memory formation. The crucial role of the entorhinal cortex in forming new memories has been well established, and the neuropeptide cholecystokinin (CCK) is reported to be released from the entorhinal cortex to enable neocortical associated memory and long-term potentiation. Though several studies reveal that the entorhinal cortex and CCK are related to AD, it is less well studied. It is unclear whether CCK is a good biomarker or further a great drug candidate for AD. mRNA expressions of CCK and CCK-B receptor (CCKBR) were examined in two mouse models, 3xTg AD and CCK knock-out (CCK Aged 3xTg AD mice exhibited reduced CCK mRNA expression in the entorhinal cortex but reduced CCKBR expression in the neocortex and hippocampus, and impaired cognition and neuroplasticity comparable with CCK Here we provide more evidence to support the role of CCK in learning and memory and its potential to treat AD. We elaborated on the rescue effect of a promising novel drug, HT-267, on aged 3xTg AD mice. Although the physiological etiology of CCK in AD still needs to be further investigated, this study sheds light on a potential pharmaceutical candidate for AD and dementia.

Sections du résumé

BACKGROUND BACKGROUND
As one major symptom of Alzheimer's disease (AD), anterograde amnesia describes patients with an inability in new memory formation. The crucial role of the entorhinal cortex in forming new memories has been well established, and the neuropeptide cholecystokinin (CCK) is reported to be released from the entorhinal cortex to enable neocortical associated memory and long-term potentiation. Though several studies reveal that the entorhinal cortex and CCK are related to AD, it is less well studied. It is unclear whether CCK is a good biomarker or further a great drug candidate for AD.
METHODS METHODS
mRNA expressions of CCK and CCK-B receptor (CCKBR) were examined in two mouse models, 3xTg AD and CCK knock-out (CCK
RESULTS RESULTS
Aged 3xTg AD mice exhibited reduced CCK mRNA expression in the entorhinal cortex but reduced CCKBR expression in the neocortex and hippocampus, and impaired cognition and neuroplasticity comparable with CCK
CONCLUSIONS CONCLUSIONS
Here we provide more evidence to support the role of CCK in learning and memory and its potential to treat AD. We elaborated on the rescue effect of a promising novel drug, HT-267, on aged 3xTg AD mice. Although the physiological etiology of CCK in AD still needs to be further investigated, this study sheds light on a potential pharmaceutical candidate for AD and dementia.

Identifiants

pubmed: 38750512
doi: 10.1186/s13195-024-01472-1
pii: 10.1186/s13195-024-01472-1
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

109

Subventions

Organisme : Hong Kong Research Grants Council, General Research Fund
ID : 11103220, 11103922, 11101818
Organisme : Hong Kong Research Grants Council, Collaborative Research Fund
ID : C1043-21G
Organisme : Hong Kong Research Grants Council, Theme-Based Research Scheme
ID : T13-605/18-W
Organisme : Innovation and Technology Fund
ID : GHP_075_19GD
Organisme : Health and Medical Research Fund
ID : 08194106, 09203656

Informations de copyright

© 2024. The Author(s).

Références

Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239–59.
pubmed: 1759558 doi: 10.1007/BF00308809
Hardy J., Selkoe D. J. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353–6.
pubmed: 12130773 doi: 10.1126/science.1072994
Mattson MP. Pathways towards and away from Alzheimer’s disease. Nature. 2004;430(7000):631–9.
pubmed: 15295589 pmcid: 3091392 doi: 10.1038/nature02621
Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer’s disease. Cereb Cortex. 1991;1(1):103–16.
pubmed: 1822725 doi: 10.1093/cercor/1.1.103
Braak H, Braak EVA. Staging of Alzheimer’s disease-related neurofibrillary changes. Neurobiol Aging. 1995;16(3):271–8.
pubmed: 7566337 doi: 10.1016/0197-4580(95)00021-6
Cummings BJ, Pike CJ, Shankle R, Cotman CW. β-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer’s disease. Neurobiol Aging. 1996;17(6):921–33.
pubmed: 9363804 doi: 10.1016/S0197-4580(96)00170-4
Näslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD. Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline. JAMA. 2000;283(12):1571–7.
pubmed: 10735393 doi: 10.1001/jama.283.12.1571
Du AT, Schuff N, Amend D, Laakso MP, Hsu YY, Jagust WJ, Weiner MW. Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2001;71(4):441–7.
pubmed: 11561025 doi: 10.1136/jnnp.71.4.441
Di Paola M, Macaluso E, Carlesimo GA, Tomaiuolo F, Worsley KJ, Fadda L, Caltagirone C. Episodic memory impairment in patients with Alzheimer’s disease is correlated with entorhinal cortex atrophy. J Neurol. 2007;254(6):774–81.
pubmed: 17404777 doi: 10.1007/s00415-006-0435-1
Morrison JH, Hof PR. Life and death of neurons in the aging brain. Science. 1997;278(5337):412–9.
pubmed: 9334292 doi: 10.1126/science.278.5337.412
Yeh C. Y., Vadhwana B., Verkhratsky A., Rodríguez J. J. Early astrocytic atrophy in the entorhinal cortex of a triple transgenic animal model of Alzheimer’s disease. ASN Neuro. 2011;3(5):AN20110025.
doi: 10.1042/AN20110025
Squire LR. The legacy of patient HM for neuroscience. Neuron. 2009;61(1):6–9.
pubmed: 19146808 pmcid: 2649674 doi: 10.1016/j.neuron.2008.12.023
Milner B, Klein D. Loss of recent memory after bilateral hippocampal lesions: memory and memories-looking back and looking forward. J Neurol Neurosurg Psychiatry. 2016;87:230.
pubmed: 26283686 doi: 10.1136/jnnp-2015-311092
Scoville WB, Milner B. Loss of recent memory after bilateral hippocampal lesions. J Neurol Neurosurg Psychiatry. 1957;20(1):11.
pubmed: 13406589 pmcid: 497229 doi: 10.1136/jnnp.20.1.11
Canto CB, Wouterlood FG, Witter MP. What does the anatomical organization of the entorhinal cortex tell us? Neural Plast. 2008;2008: 381243.
pubmed: 18769556 pmcid: 2526269 doi: 10.1155/2008/381243
Swanson LW, Kohler C. Anatomical evidence for direct projections from the entorhinal area to the entire cortical mantle in the rat. The Journal of neuroscience : the official journal of the Society for Neuroscience. 1986;6:3010–23.
pubmed: 3020190 doi: 10.1523/JNEUROSCI.06-10-03010.1986
Li X, Yu K, Zhang Z, Sun W, Yang Z, Feng J, He J. Cholecystokinin from the entorhinal cortex enables neural plasticity in the auditory cortex. Cell Research. 2014;24(3):307–30.
pubmed: 24343575 doi: 10.1038/cr.2013.164
Greenwood RS, Godar SE, Reaves TA Jr, Hayward JN. Cholecystokinin in hippocampal pathways. J Comp Neurol. 1981;203:335–50.
pubmed: 7320233 doi: 10.1002/cne.902030303
Innis RB, Correa FM, Uhl GR, Schneider B, Snyder SH. Cholecystokinin octapeptide-like immunoreactivity: histochemical localization in rat brain. Proc Natl Acad Sci USA. 1979;76:521–5.
pubmed: 284371 pmcid: 382974 doi: 10.1073/pnas.76.1.521
Kohler C, Chan-Palay V. The distribution of cholecystokinin-like immunoreactive neurons and nerve terminals in the retrohippocampal region in the rat and guinea pig. J Comp Neurol. 1982;210:136–46.
pubmed: 6290546 doi: 10.1002/cne.902100204
Larsson LI, Rehfeld JF. Localization and molecular heterogeneity of cholecystokinin in the central and peripheral nervous system. Brain Res. 1979;165(2):201–18.
pubmed: 369662 doi: 10.1016/0006-8993(79)90554-7
Wank SA. Cholecystokinin receptors. Am J Physiol Gastrointest Liver Physiol. 1995;269(5):G628–46.
doi: 10.1152/ajpgi.1995.269.5.G628
Chen X, Guo Y, Feng J, Liao Z, Li X, Wang H, He J. Encoding and retrieval of artificial visuoauditory memory traces in the auditory cortex requires the entorhinal cortex. J Neurosci. 2013;33(24):9963–74.
pubmed: 23761892 pmcid: 6618393 doi: 10.1523/JNEUROSCI.4078-12.2013
Chen X, Li X, Wong YT, Zheng X, Wang H, Peng Y, He J. Cholecystokinin release triggered by NMDA receptors produces LTP and sound-sound associative memory. Proc Natl Acad Sci U S A. 2019;116(13):6397–406.
pubmed: 30850520 pmcid: 6442640 doi: 10.1073/pnas.1816833116
Zhang Z, Zheng X, Sun W, Peng Y, Guo Y, Lu D, He J. Visuoauditory associative memory established with cholecystokinin under anesthesia is retrieved in behavioral contexts. J Neurosci. 2020;40(10):2025–37.
pubmed: 31980587 pmcid: 7055132 doi: 10.1523/JNEUROSCI.1673-19.2019
Feng H, Su J, Fang W, Chen X, He J. The entorhinal cortex modulates trace fear memory formation and neuroplasticity in the mouse lateral amygdala via cholecystokinin. Elife. 2021;10: e69333.
pubmed: 34779397 pmcid: 8629425 doi: 10.7554/eLife.69333
Roussarie JP, Yao V, Rodriguez-Rodriguez P, Oughtred R, Rust J, Plautz Z, Greengard P. Selective neuronal vulnerability in Alzheimer’s disease: a network-based analysis. Neuron. 2020;107(5):821–35.
pubmed: 32603655 pmcid: 7580783 doi: 10.1016/j.neuron.2020.06.010
Plagman A., Hoscheidt S., McLimans K. E., Klinedinst B., Pappas C., Anantharam V., Alzheimer’s Disease Neuroimaging Initiative. Cholecystokinin and Alzheimer’s disease: a biomarker of metabolic function, neural integrity, and cognitive performance. Neurobiol Aging. 2019;76:201–7.
pubmed: 30739077 pmcid: 6425756 doi: 10.1016/j.neurobiolaging.2019.01.002
Vorhees CV, Williams MT. Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat Protoc. 2006;1(2):848.
pubmed: 17406317 pmcid: 2895266 doi: 10.1038/nprot.2006.116
Cole J, Ertoy D, Lin H, Sutliff RL, Ezan E, Guyene TT, Bernstein KE. Lack of angiotensin II–facilitated erythropoiesis causes anemia in angiotensin-converting enzyme–deficient mice. J Clin Invest. 2000;106(11):1391–8.
pubmed: 11104792 pmcid: 381466 doi: 10.1172/JCI10557
Koulischer D, Moroder L, Deschodt-Lanckman M. Degradation of cholecystokinin octapeptide, related fragments and analogs by human and rat plasma in vitro. Regul Pept. 1982;4(3):127–39.
pubmed: 6291099 doi: 10.1016/0167-0115(82)90080-5
Tortorella MD, He JF. Polypeptide and application thereof as cck receptor agonist/antagonists. CN113929737A (Granted) filed October 20, 2021. PCT/CN2022/102744 filed April 27, 2023. https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2023065716 .
Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, LaFerla FM. Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular Aβ and synaptic dysfunction. Neuron. 2003;39(3):409–21.
Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM. Intraneuronal Aβ causes the onset of early Alzheimer’s disease-related cognitive deficits in transgenic mice. Neuron. 2005;45(5):675–88.
pubmed: 15748844 doi: 10.1016/j.neuron.2005.01.040
Sterniczuk R, Antle MC, LaFerla FM, Dyck RH. Characterization of the 3xTg-AD mouse model of Alzheimer’s disease: part 2. Behavioral and cognitive changes Brain research. 2010;1348:149–55.
pubmed: 20558146
Gimenez-Llort L, Blazquez G, Canete T, Johansson B, Oddo S, Tobena A, Fernandez-Teruel A. Modeling behavioral and neuronal symptoms of Alzheimer’s disease in mice: a role for intraneuronal amyloid. Neurosci Biobehav Rev. 2007;31(1):125–47.
pubmed: 17055579 doi: 10.1016/j.neubiorev.2006.07.007
Kovács KA. Relevance of a Novel Circuit-Level Model of Episodic Memories to Alzheimer’s Disease. Int J Mol Sci. 2021;23(1):462.
pubmed: 35008886 pmcid: 8745479 doi: 10.3390/ijms23010462
Antunes M, Biala G. The novel object recognition memory: neurobiology, test procedure, and its modifications. Cogn Process. 2012;13(2):93–110.
pubmed: 22160349 doi: 10.1007/s10339-011-0430-z
Gómez-Isla T, Price JL, McKeel DW Jr, Morris JC, Growdon JH, Hyman BT. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer’s disease. J Neurosci. 1996;16(14):4491–500.
pubmed: 8699259 pmcid: 6578866 doi: 10.1523/JNEUROSCI.16-14-04491.1996
Kordower JH, Chu Y, Stebbins GT, DeKosky ST, Cochran EJ, Bennett D, Mufson EJ. Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society. 2001;49(2):202–13.
doi: 10.1002/1531-8249(20010201)49:2<202::AID-ANA40>3.0.CO;2-3
Tward D. J., Sicat C. S., Brown T., Bakker A., Gallagher M., Albert M., Alzheimer’s Disease Neuroimaging Initiative. Entorhinal and transentorhinal atrophy in mild cognitive impairment using longitudinal diffeomorphometry. Alzheimers Dement (Amst). 2017;9:41–50.
pubmed: 28971142 doi: 10.1016/j.dadm.2017.07.005
Casey D. A., Antimisiaris D., O’Brien J. Drugs for Alzheimer’s disease: are they effective? Pharmacy and Therapeutics. 2010;35(4):208.v.
Bachurin SO, Bovina EV, Ustyugov AA. Drugs in clinical trials for Alzheimer’s disease: the major trends. Med Res Rev. 2017;37(5):1186–225.
pubmed: 28084618 doi: 10.1002/med.21434
Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, O’Gorman J. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature. 2016;537(7618):50–6.
pubmed: 27582220 doi: 10.1038/nature19323

Auteurs

Nan Zhang (N)

Department of Neuroscience and Biomedical Sciences, City University of Hong Kong, Hong Kong SAR, 0000, P.R. China.
Centre for Regenerative Medicine and Health, Hong Kong Institute of Science & Innovation, Chinese Academy of Sciences, Hong Kong SAR, 0000, P.R. China.

Yixuan Sui (Y)

Department of Neuroscience and Biomedical Sciences, City University of Hong Kong, Hong Kong SAR, 0000, P.R. China.

Peter Jendrichovsky (P)

Department of Neuroscience and Biomedical Sciences, City University of Hong Kong, Hong Kong SAR, 0000, P.R. China.
Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, 21205, USA.

Hemin Feng (H)

Department of Neuroscience and Biomedical Sciences, City University of Hong Kong, Hong Kong SAR, 0000, P.R. China.
Department of Neurosurgery, Stanford University, Stanford, CA, 94305, USA.

Heng Shi (H)

Department of Neuroscience and Biomedical Sciences, City University of Hong Kong, Hong Kong SAR, 0000, P.R. China.
Centre for Regenerative Medicine and Health, Hong Kong Institute of Science & Innovation, Chinese Academy of Sciences, Hong Kong SAR, 0000, P.R. China.

Xu Zhang (X)

Department of Neuroscience and Biomedical Sciences, City University of Hong Kong, Hong Kong SAR, 0000, P.R. China.
National Engineering Laboratory of Big Data System Computing Technology, Shenzhen University, Shenzhen, 518507, P.R. China.

Shenghui Xu (S)

Department of Neuroscience and Biomedical Sciences, City University of Hong Kong, Hong Kong SAR, 0000, P.R. China.
Laboratory Testing Division, WuXi AppTec (Suzhou) Co., Ltd, Suzhou, 215104, P.R. China.

Wenjian Sun (W)

Department of Neuroscience and Biomedical Sciences, City University of Hong Kong, Hong Kong SAR, 0000, P.R. China.
Zilkha Neurogenetic Institute, University of Southern California, Los Angeles, CA, 90033, USA.

Huatang Zhang (H)

Centre for Regenerative Medicine and Health, Hong Kong Institute of Science & Innovation, Chinese Academy of Sciences, Hong Kong SAR, 0000, P.R. China.

Xi Chen (X)

Department of Neuroscience and Biomedical Sciences, City University of Hong Kong, Hong Kong SAR, 0000, P.R. China.

Micky D Tortorella (MD)

Centre for Regenerative Medicine and Health, Hong Kong Institute of Science & Innovation, Chinese Academy of Sciences, Hong Kong SAR, 0000, P.R. China. m.tortorella@grmh-gdl.cn.
Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 510530, P.R. China. m.tortorella@grmh-gdl.cn.

Jufang He (J)

Department of Neuroscience and Biomedical Sciences, City University of Hong Kong, Hong Kong SAR, 0000, P.R. China. jufanghe@cityu.edu.hk.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH